Tests an AI heart tool to find hidden heart failure in diabetes patients
Tests whether AI heart scan results and advice help people with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes
Key facts
- Where
- Dallas, United StatesSee the site
Where in United States
- UT Southwestern Medical CenterDallas, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Texas Southwestern Medical Center
- Trial code
- NCT06593314
- Record updated
- 5 November 2026
- Original description
A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.Read full original descriptionShow less
Identifying Undiagnosed HFpEF Among Patients With Type 2 Diabetes Using Ultromics AI HFpEF Algorithm
A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.
Inclusion: Patients with diagnosis of Type 2 diabetes and High WATCH DM score; Echocardiogram available in last 6-months.
Exclusion: History of HF; Not eligible for prescription of new GLP-1RA or SGLT2i or ns-MRA; Corresponding providers to patients identified by the above inclusion exclusion criteria will be included in the clinical trial of the decision support tool.
Clinical cohort inclusion exclusion criteria:.